Why PRP works only on certain patients with tennis elbow? Is PDGFB gene a key for PRP therapy effectiveness? A prospective cohort study.
PDGFB
Platelet-rich plasma
Tendinopathy
Tennis elbow
single nucleotide polymorphisms, gene
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
18 Aug 2021
18 Aug 2021
Historique:
received:
10
06
2021
accepted:
07
08
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
21
8
2021
Statut:
epublish
Résumé
There is variability in individual response to platelet-rich plasma (PRP) therapy in tennis elbow treatment. Genetic variation, especially within genes encoding growth factors may influence the observed inter-individual differences. The purpose of this study was to identify polymorphic variants of the platelet-derived growth factor beta polypeptide gene (PDGFB) that determine an improved individual response to PRP therapy in tennis elbow patients. This prospective cohort study was designed in accordance with STROBE and MIBO guidelines. A cohort of 107 patients (132 elbows, 25 bilateral) was studied, including 65 females (77 elbows) and 42 males (55 elbows), aged 24-64 years (median 46.00 ± 5.50), with lateral elbow tendinopathy treated with autologous PRP injection. The effectiveness of PRP therapy was recorded in all subjects at 2, 4, 8, 12, 24 and 52 weeks after PRP injection using the Visual Analog Scale (VAS), quick version of Disabilities of the Arm, Shoulder and Hand score (QDASH) and Patient-Rated Tennis Elbow Evaluation (PRTEE). In order to determine the PDGFB variants with the best response to PRP therapy, patient reported outcome measures were compared between individual genotypes within studied polymorphic variants (rs2285099, rs2285097, rs2247128, rs5757572, rs1800817 and rs7289325). The influence of single nucleotide polymorphisms on blood and PRP parameters, including the concentration of PDGF-AB and PDGF-BB proteins was also analyzed. Our analysis identified genetic variants of the PDGFB gene that lead to a better response to PRP therapy. The TT (rs2285099) and CC (rs2285097) homozygotes had higher concentration of platelets in whole blood than carriers of other genotypes (p = 0.018) and showed significantly (p < 0.05) lower values of VAS (weeks 2-12), QDASH and PRTEE (weeks 2-24). The rs2285099 and rs2285097 variants formed strong haplotype block (r PDGFB gene's polymorphisms increase the effectiveness of PRP therapy in tennis elbow treatment. Genotyping two polymorphisms of the PDGFB gene, namely rs2285099 (or rs2285097) and rs2247128 may be a helpful diagnostic tool while assessing patients for PRP therapy and modifying the therapy to improve its effectiveness.
Sections du résumé
BACKGROUND
BACKGROUND
There is variability in individual response to platelet-rich plasma (PRP) therapy in tennis elbow treatment. Genetic variation, especially within genes encoding growth factors may influence the observed inter-individual differences. The purpose of this study was to identify polymorphic variants of the platelet-derived growth factor beta polypeptide gene (PDGFB) that determine an improved individual response to PRP therapy in tennis elbow patients.
METHODS
METHODS
This prospective cohort study was designed in accordance with STROBE and MIBO guidelines. A cohort of 107 patients (132 elbows, 25 bilateral) was studied, including 65 females (77 elbows) and 42 males (55 elbows), aged 24-64 years (median 46.00 ± 5.50), with lateral elbow tendinopathy treated with autologous PRP injection. The effectiveness of PRP therapy was recorded in all subjects at 2, 4, 8, 12, 24 and 52 weeks after PRP injection using the Visual Analog Scale (VAS), quick version of Disabilities of the Arm, Shoulder and Hand score (QDASH) and Patient-Rated Tennis Elbow Evaluation (PRTEE). In order to determine the PDGFB variants with the best response to PRP therapy, patient reported outcome measures were compared between individual genotypes within studied polymorphic variants (rs2285099, rs2285097, rs2247128, rs5757572, rs1800817 and rs7289325). The influence of single nucleotide polymorphisms on blood and PRP parameters, including the concentration of PDGF-AB and PDGF-BB proteins was also analyzed.
RESULTS
RESULTS
Our analysis identified genetic variants of the PDGFB gene that lead to a better response to PRP therapy. The TT (rs2285099) and CC (rs2285097) homozygotes had higher concentration of platelets in whole blood than carriers of other genotypes (p = 0.018) and showed significantly (p < 0.05) lower values of VAS (weeks 2-12), QDASH and PRTEE (weeks 2-24). The rs2285099 and rs2285097 variants formed strong haplotype block (r
CONCLUSIONS
CONCLUSIONS
PDGFB gene's polymorphisms increase the effectiveness of PRP therapy in tennis elbow treatment. Genotyping two polymorphisms of the PDGFB gene, namely rs2285099 (or rs2285097) and rs2247128 may be a helpful diagnostic tool while assessing patients for PRP therapy and modifying the therapy to improve its effectiveness.
Identifiants
pubmed: 34407802
doi: 10.1186/s12891-021-04593-y
pii: 10.1186/s12891-021-04593-y
pmc: PMC8375168
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
710Subventions
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-008/N/7/K and KNW-1-031/K/8/O
Informations de copyright
© 2021. The Author(s).
Références
Biochemistry. 1990 Jan 9;29(1):166-72
pubmed: 2322537
BMJ Open Sport Exerc Med. 2017 Nov 6;3(1):e000237
pubmed: 29177072
Am J Sports Med. 2017 Jan;45(1):226-233
pubmed: 27268111
Breast Cancer Res Treat. 2013 Aug;140(3):587-601
pubmed: 23912956
Orthop Traumatol Surg Res. 2019 Dec;105(8S):S241-S246
pubmed: 31543413
Nature. 1986 Apr 24-30;320(6064):695-9
pubmed: 3754619
Orthop J Sports Med. 2017 Aug 23;5(8):2325967117724416
pubmed: 28856171
Int J Mol Sci. 2020 Feb 16;21(4):
pubmed: 32079117
Nature. 1985 Aug 22-28;316(6030):748-50
pubmed: 4033772
Bioinformatics. 2005 Jan 15;21(2):263-5
pubmed: 15297300
Am J Sports Med. 2018 Feb;46(2):409-419
pubmed: 29211968
Asian Pac J Cancer Prev. 2015;16(14):5647-54
pubmed: 26320430
Eur Cell Mater. 2017 Jul 17;34:15-39
pubmed: 28714058
Genes Dev. 2008 May 15;22(10):1276-312
pubmed: 18483217
BMC Musculoskelet Disord. 2013 Jul 26;14:221
pubmed: 23890452
Am J Hum Genet. 2017 Jul 6;101(1):5-22
pubmed: 28686856
Cancer Sci. 2019 Jun;110(6):2022-2032
pubmed: 30972876
FEBS Open Bio. 2017 Oct 16;7(11):1722-1736
pubmed: 29123981
Adv Wound Care (New Rochelle). 2020 Dec;9(12):657-675
pubmed: 33124966
Muscles Ligaments Tendons J. 2014 May 08;4(1):63-5
pubmed: 24932449
Science. 2002 Jun 21;296(5576):2225-9
pubmed: 12029063
Sci Rep. 2019 Nov 26;9(1):17627
pubmed: 31772230
J Oral Implantol. 2014 Jun;40(3):330-40
pubmed: 24914921
Front Aging Neurosci. 2015 Dec 10;7:228
pubmed: 26696880
Br J Sports Med. 2016 Aug;50(15):900-8
pubmed: 26392595
Cell Adh Migr. 2014;8(6):595-602
pubmed: 25482626